Business context and reporting period
The supplied filing is Novus Therapeutics, Inc.’s Form 10-K for the fiscal year ended December 31, 2018, filed March 27, 2019. It is not identified as an Eledon Pharmaceuticals filing; verify the issuer before relying on this summary. Novus was a clinical-stage ENT-focused pharmaceutical company, with OP0201, a nasal surfactant drug-device candidate for otitis media, as its lead program. The company reported one operating segment and no product revenue.
Financial performance and position
| Metric | 2018 | 2017 |
|---|---|---|
| Revenue | None from product sales | None from product sales |
| Research and development expense | $6.817 million | $2.022 million |
| General and administrative expense | $7.243 million | $11.099 million |
| Total operating expenses | $14.060 million | $13.121 million |
| Net loss | $14.065 million | $13.116 million |
| Net loss per share, basic and diluted | $1.56 | $2.30 |
| Cash used in operating activities | $11.893 million | $14.941 million |
| Cash and cash equivalents at year-end | $12.972 million | $17.233 million |
| Working capital | $11.7 million | Not clearly stated |
| Total liabilities | $2.534 million | $1.440 million |
Gross margin is not applicable because the company had no product sales. The filing reports no debt balance in the presented balance sheet; it does not provide a separate debt metric. Cash declined by $4.331 million during 2018. Financing activities provided $7.562 million, principally from at-the-market common-stock sales. The company reported a $41.571 million accumulated deficit.
Changes versus the prior year
- R&D expense rose $4.795 million, primarily due to OP0201 formulation/device development, clinical development, and added clinical and regulatory personnel.
- G&A expense fell $3.856 million, mainly because merger-related expenses declined by $5.1 million, partly offset by higher public-company and personnel costs.
- Net loss increased by $949,000 despite lower operating cash use, reflecting noncash expenses and working-capital movements.
- Cash and cash equivalents fell from $17.233 million to $12.972 million. Common shares outstanding increased from 7.11 million to 9.42 million, including shares sold through the equity distribution agreement.
Outlook, risks, and unusual items
- Going concern: Management concluded substantial doubt existed about the company’s ability to continue as a going concern for twelve months after issuance of the financial statements. It said available cash was expected to fund ongoing Phase 1 studies, but additional financing would be needed for further OP0201 development. No financing was assured.
- Funding plans: Management contemplated raising capital, including equity financing. If sufficient funding was not secured, it described possible cost reductions, including personnel cuts and delaying or curtailing R&D. The filing also refers to seeking strategic alternatives. Further equity financing could dilute existing shareholders.
- Development: The filing describes four OP0201 trials: three Phase 1 studies and an exploratory Phase 2a pediatric study. The company planned to pursue subsequent Phase 2 and Phase 3 studies if the ongoing studies supported advancement. These are plans, not reported outcomes.
- Concentration and execution risks: The company had not qualified a secondary supplier for OP0201’s active ingredients or a secondary manufacturer, and noted manufacturing scale-up, clinical, regulatory, and financing risks. OP0102 development was paused to focus resources on OP0201.
- Legal contingency: The filing describes consolidated securities litigation relating to Tokai’s 2014 IPO. The company said it could not predict the outcome or estimate a reasonably possible loss; no liability was accrued for the described matters.
- Other obligations: Operating lease commitments totaled $514,000, with $180,000 due within one year. The OP0201 license includes up to $42.1 million in development/regulatory milestones, up to $36.0 million in sales milestones, and tiered royalties; no milestones were achieved in 2018 or 2017.
- Controls: Management reported effective disclosure controls and internal control over financial reporting as of year-end. The auditor did not provide an internal-control attestation.
Important facts for investors to verify
- Confirm the filing issuer: the document is for Novus Therapeutics, Inc., not Eledon Pharmaceuticals, Inc.
- Check subsequent filings for financing, cash runway, cost reductions, strategic alternatives, and whether the going-concern uncertainty was resolved.
- Verify current OP0201 trial status and results, and whether the program advanced to later-stage trials.
- Review subsequent disclosures on the Tokai IPO litigation and any developments affecting potential losses.
- Assess dilution and remaining availability under the 2018 equity prospectus, which permitted up to $8.8 million in sales and had no sales as of December 31, 2018.